Aura Biosciences (NASDAQ:AURA) Releases Earnings Results, Beats Estimates By $0.06 EPS

Aura Biosciences (NASDAQ:AURA – Get Rating) issued its quarterly earnings data on Wednesday. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.06, Yahoo Finance reports.

Aura Biosciences Stock Up 0.4 %

Shares of NASDAQ AURA opened at $10.25 on Friday. Aura Biosciences has a 1 year low of $9.43 and a 1 year high of $24.83. The stock has a fifty day moving average price of $10.55 and a two-hundred day moving average price of $12.30.

Analyst Upgrades and Downgrades

Separately, JMP Securities dropped their price target on shares of Aura Biosciences from $30.00 to $25.00 and set an “outperform” rating on the stock in a research report on Thursday.

Insider Transactions at Aura Biosciences

In other news, Director David Michael Johnson bought 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 28th. The stock was acquired at an average price of $9.75 per share, with a total value of $39,000.00. Following the completion of the purchase, the director now directly owns 17,000 shares of the company’s stock, valued at approximately $165,750. The acquisition was disclosed in a filing with the SEC, which is available at this link. Company insiders own 5.00% of the company’s stock.

Institutional Trading of Aura Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp bought a new stake in Aura Biosciences during the first quarter worth approximately $319,000. BlackRock Inc. boosted its position in shares of Aura Biosciences by 15.2% in the 1st quarter. BlackRock Inc. now owns 275,027 shares of the company’s stock valued at $6,050,000 after purchasing an additional 36,244 shares during the period. Vanguard Group Inc. increased its stake in Aura Biosciences by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 228,633 shares of the company’s stock worth $5,030,000 after purchasing an additional 2,375 shares in the last quarter. Nantahala Capital Management LLC raised its holdings in Aura Biosciences by 204.6% during the 1st quarter. Nantahala Capital Management LLC now owns 301,990 shares of the company’s stock worth $6,644,000 after buying an additional 202,844 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in Aura Biosciences by 30.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 15,379 shares of the company’s stock valued at $339,000 after buying an additional 3,557 shares in the last quarter. 55.63% of the stock is currently owned by institutional investors.

About Aura Biosciences

(Get Rating)

Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.